Sequence 17 from Patent US 20100279918

General Information


DRACP ID  DRACP01309

Peptide Name   Sequence 17 from Patent US 20100279918

Sequence  GALFLGWLGAAGSTMGAPKKKRKV

Sequence Length  24

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic construct

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01309

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C112H186N32O27S

Absent amino acids  CDEHINQY

Common amino acids  G

Mass  285541

Pl  12

Basic residues  5

Acidic residues  0

Hydrophobic residues  10

Net charge  5

Boman Index  -469

Hydrophobicity  5.83

Aliphatic Index  77.5

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: >10 hour

Extinction Coefficient cystines  5500

Absorbance 280nm  239.13

Polar residues  7

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2010/0279918 A1

Patent Title  Chimeric Constructs Between Cancer-Homing Peptides and Cell-Penetrating Peptides Coupled to Anticancer Drugs and/or Diagnostic Agent/Agents.

Other Iinformation  Granted Patent Family: 7s / 7ex; Family Jurisdictions: DE, EP, WO, AT, US; Legal Status: Discontinued; Application No: 22536707; Filed:Mar 20, 2007; Published: Nov 4, 2010; Earliest Priority: Mar 20, 2006;

Other Published ID  DE602007011901D1  EP1991586A1  EP1991586B1  WO2007108749A1  WO2007108749A8 




DRACP is developed by Dr.Zheng's team.